Massachusetts Cuts Health Coverage By $115 Million
"Overseers of Massachusetts" trailblazing health care program made their first cuts recently, trimming $115 million, or 12 percent, from Commonwealth Care, which subsidizes premiums for needy residents and is the centerpiece of the 2006 law," according to the Boston Globe. The Connector Authority board made the cuts in response to two recession side effects: "the state budget crisis and a surge in enrollment by the recently unemployed." Commonwealth Care"s enrollment has increased in the last three months from 165,000 member to 177,000 members, and is projected to grow to 212,000 next year.
Endocrinology
Pages: 1 [2]
Amgen Announces KRAS Safety Update To U.S. Prescribing Information For Vectibix(R) (Panitumumab)
prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release. AmgenPages: 1 [2]